Published in J Exp Med on March 01, 1981
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A (2003) 4.56
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J Exp Med (2011) 3.89
Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun (1992) 3.80
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med (1998) 3.32
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol (1994) 3.12
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
Inhibitory and bactericidal effects of hydrogen peroxide production by Streptococcus pneumoniae on other inhabitants of the upper respiratory tract. Infect Immun (2000) 2.91
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun (2001) 2.55
Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun (1994) 2.51
Characterization of the cassette containing genes for type 3 capsular polysaccharide biosynthesis in Streptococcus pneumoniae. J Exp Med (1995) 2.36
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
The importance of natural IgM: scavenger, protector and regulator. Nat Rev Immunol (2010) 2.23
Antibody-independent, interleukin-17A-mediated, cross-serotype immunity to pneumococci in mice immunized intranasally with the cell wall polysaccharide. Infect Immun (2006) 2.20
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun (2001) 2.19
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun (1982) 2.19
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med (1992) 2.15
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol (2007) 2.09
The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. Infect Immun (2009) 2.09
Murine monoclonal antibodies specific for virulent Treponema pallidum (Nichols). Infect Immun (1982) 2.08
Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev (1998) 2.06
B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J Exp Med (2002) 2.01
FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med (2004) 1.95
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest (2004) 1.94
Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect Immun (1990) 1.89
Role of genetic resistance in invasive pneumococcal infection: identification and study of susceptibility and resistance in inbred mouse strains. Infect Immun (2001) 1.86
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med (2008) 1.82
The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol (2001) 1.77
The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe (2007) 1.69
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
Positive correlation between tyrosine phosphorylation of CpsD and capsular polysaccharide production in Streptococcus pneumoniae. J Bacteriol (2003) 1.64
I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med (2002) 1.63
Dual role for B-1a cells in immunity to influenza virus infection. J Exp Med (2008) 1.60
Role of inflammatory mediators in resistance and susceptibility to pneumococcal infection. Infect Immun (2002) 1.59
Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A (2001) 1.59
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
Normal mice express idiotypes related to autoantibody idiotypes of lupus mice. Proc Natl Acad Sci U S A (1983) 1.50
Immunochemical similarities between monoclonal antibacterial Waldenstrom's macroglobulins and monoclonal anti-DNA lupus autoantibodies. J Exp Med (1985) 1.49
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Protection against pneumococcal infection in mice conferred by phosphocholine-binding antibodies: specificity of the phosphocholine binding and relation to several types. Infect Immun (1983) 1.46
Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae. PLoS Pathog (2007) 1.46
Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol (1983) 1.45
Capsule biosynthesis and basic metabolism in Streptococcus pneumoniae are linked through the cellular phosphoglucomutase. J Bacteriol (2000) 1.42
Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun (2008) 1.42
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med (2007) 1.39
Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae. Infect Immun (1992) 1.35
Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. Infect Immun (2012) 1.32
Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms. J Exp Med (2002) 1.30
Phagocytosis and killing of salmonella typhimurium by peritoneal exudate cells. Infect Immun (1981) 1.29
Essential role for cellular phosphoglucomutase in virulence of type 3 Streptococcus pneumoniae. Infect Immun (2001) 1.27
Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun (1990) 1.26
Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun (2007) 1.25
Innate-like B cells. Springer Semin Immunopathol (2005) 1.24
B-1 cells in the bone marrow are a significant source of natural IgM. Eur J Immunol (2011) 1.23
IgM in microbial infections: taken for granted? Immunol Lett (2009) 1.23
Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect Immun (2002) 1.23
The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med (2013) 1.21
The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK. Clin Exp Immunol (1993) 1.17
Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun (2003) 1.15
Facultative role of germinal centers and T cells in the somatic diversification of IgVH genes. J Exp Med (1995) 1.14
The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development. Mol Cell Biol (2011) 1.14
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun (2009) 1.13
Involvement of potD in Streptococcus pneumoniae polyamine transport and pathogenesis. Infect Immun (2006) 1.09
Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun (2003) 1.09
Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun (2004) 1.09
Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae. Infect Immun (1985) 1.08
Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun (2000) 1.08
Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev (2008) 1.07
Altered Ig levels and antibody responses in mice deficient for the Fc receptor for IgM (FcμR). Proc Natl Acad Sci U S A (2012) 1.07
Antigen-specific memory in B-1a and its relationship to natural immunity. Proc Natl Acad Sci U S A (2012) 1.07
A new model of pneumococcal lipoteichoic acid structure resolves biochemical, biosynthetic, and serologic inconsistencies of the current model. J Bacteriol (2008) 1.05
Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc Natl Acad Sci U S A (2013) 1.04
Apoptosis-like death in bacteria induced by HAMLET, a human milk lipid-protein complex. PLoS One (2011) 1.03
Determination of antibodies to pneumococcal C polysaccharide in patients with community-acquired pneumonia. J Clin Microbiol (1985) 1.02
The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection. Clin Exp Immunol (1983) 1.02
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Class and subclass anti-pneumococcal antibody responses in splenectomized patients. Clin Exp Immunol (1985) 0.98
Human B-1 cells take the stage. Ann N Y Acad Sci (2013) 0.97
Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats. Infect Immun (1997) 0.97
The link between antibodies to OxLDL and natural protection against pneumococci depends on D(H) gene conservation. J Exp Med (2013) 0.97
Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun (2006) 0.96
Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias. J Infect Dis (2011) 0.96
Initiation and synthesis of the Streptococcus pneumoniae type 3 capsule on a phosphatidylglycerol membrane anchor. J Bacteriol (2005) 0.95
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection. MBio (2013) 0.94
STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III. J Exp Med (1944) 24.08
A SEROLOGICAL DIFFERENTIATION OF HUMAN AND OTHER GROUPS OF HEMOLYTIC STREPTOCOCCI. J Exp Med (1933) 10.79
CHEMICAL AND IMMUNOLOGICAL PROPERTIES OF A SPECIES-SPECIFIC CARBOHYDRATE OF PNEUMOCOCCI. J Exp Med (1930) 6.69
Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. I. Evidence that an X-linked gene plays a decisive role in determining responsiveness. J Exp Med (1972) 5.19
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
THE PROTECTIVE ACTION OF TYPE I ANTIPNEUMOCOCCUS SERUM IN MICE : I. THE QUANTITATIVE ASPECTS OF THE MOUSE PROTECTION TEST. J Exp Med (1935) 4.90
Nutrition of the host and natural resistance to infection. V. An improved assay employing genetic markers in the double strain inoculation test. J Exp Med (1956) 4.81
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Pneumococcal C-substance, a ribitol teichoic acid containing choline phosphate. Biochem J (1968) 3.94
PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES. J Exp Med (1945) 3.91
X-linked B-lymphocyte immune defect in CBA/HN mice. I. Studies of the function and composition of spleen cells. J Exp Med (1975) 3.70
Genetics of a new IgVH (T15 idiotype) marker in the mouse regulating natural antibody to phosphorylcholine. J Exp Med (1974) 3.64
Pneumococcal Forssman antigen. A choline-containing lipoteichoic acid. J Biol Chem (1973) 3.31
X-linked B-lymphocyte immune defect in CBA/N mice. II. Studies of the mechanisms underlying the immune defect. J Exp Med (1975) 3.03
Specific inhibition of plaque formation to phosphorylcholine by antibody against antibody. Science (1972) 2.73
Specificity for phosphorylcholine of six murine myeloma proteins reactive with Pneumococcus C polysaccharide and beta-lipoprotein. Biochemistry (1971) 2.55
Surface immunoglobulin D as a functional receptor for a subclass of B lymphocytes. Immunol Rev (1977) 2.50
Mouse pre-B cells synthesize and secrete mu heavy chains but not light chains. Cell (1980) 2.50
ACTIVE AND PASSIVE IMMUNITY TO PNEUMOCOCCUS INFECTION INDUCED IN RABBITS BY IMMUNIZATION WITH R PNEUMOCOCCI. J Exp Med (1928) 2.44
Antigen-binding myeloma proteins in mice. Ann N Y Acad Sci (1971) 2.33
Inability of mice with a defect in B-lymphocyte maturation to respond to phosphorycholine on immunogenic carriers. J Exp Med (1977) 2.18
Clonal nature of the immune response to phosphorylcholine. IV. Idiotypic uniformity of binding site-associated antigenic determinants among mouse antiphosphorylcholine antibodies. J Exp Med (1974) 2.02
Clonal nature of the immune response to phosphorylcholine. II. Idiotypic specificity and binding characteristics of anti-phosphorylcholine antibodies. J Immunol (1974) 1.95
Susceptibility of CBA/N mice to infection with Salmonella typhimurium: influence of the X-linked gene controlling B lymphocyte function. J Immunol (1979) 1.90
Clonal nature of the immune response to phosphorylcholine. I. Specificity, class, and idiotype of phosphorylcholine-binding receptors on lymphoid cells. J Exp Med (1974) 1.85
Biological properties of an immunogenic pneumococcal subcellular preparation. Infect Immun (1976) 1.67
Surface phagocytosis; further evidence of its destructive action upon fully encapsulated pneumococci in the absence of type-specific antibody. J Exp Med (1958) 1.66
Capsulation of pneumococcus with soluble C-like (Cs) polysaccharide. I. Biological and genetic properties of Cs pneumococcal strains. J Exp Med (1968) 1.65
Genetic control of the antibody response to type 3 pneumococcal polysaccharide in mice. II. Relationship between IgM immunoglobulin levels and the ability to give an IgM antibody response. J Exp Med (1974) 1.64
Immunoglobulin subclass-specific immunodeficiency in mice with an X-linked B-lymphocyte defect. J Exp Med (1979) 1.54
Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol (1978) 1.54
Pneumococcal vaccine: development and prospects. Am J Med (1979) 1.51
Immunological unresponsiveness to thymus-independent antigens: two fundamentally different genetic mechanisms of B-cell unresponsiveness to dextran. J Exp Med (1977) 1.50
Uniformity in the clonal repertoire for the immune response to phosphorylcholine in mice. Eur J Immunol (1976) 1.46
Strain differences in the antibody plaque-forming cell responses of inbred mice to pneumococcal polysaccharide. Cell Immunol (1971) 1.46
An analysis of the defective response of CBA/N mice to T-dependent antigens. J Immunol (1975) 1.45
Kinetics of the antibody response to type III pneumococcal polysaccharide. I. Evidence that suppressor cells function by inhibiting the recruitment and proliferation of antibody-producing cells. J Immunol (1976) 1.42
A phosphorylcholine idiotype related to TEPC 15 in mice infected with Ascaris suum. J Immunol (1976) 1.27
Expression of new idiotypes following neonatal idiotypic suppression of a dominant clone. Eur J Immunol (1976) 1.23
THE EFFECT OF FORMALDEHYDE ON PNEUMOCOCCI. J Exp Med (1938) 1.19
Defective resistance to Plasmodium yoelii in CBA/N mice. J Immunol (1979) 1.18
Studies on phosphorylcholine-specific T cell idiotypes and idiotype-specific immunity. Mol Immunol (1980) 1.12
IMMUNIZATION OF EXPERIMENTAL ANIMALS WITH A SOLUBLE ANTIGEN EXTRACTED FROM PNEUMOCOCCI. J Exp Med (1938) 1.11
Immune response deficiency of BSVS mice. II. Generalized deficiency to thymus-dependent antigens. Eur J Immunol (1979) 1.10
Complete sharing of light chain spectrotypes by murine IgM and IgG anti-streptococcal antibodies. J Immunol (1977) 1.05
Phosphorylcholine-binding hybridoma proteins of normal and idiotypically suppressed BALB/c mice I. Characterization and idiotypic analysis. Eur J Immunol (1980) 1.02
Clonal nature of the immune response to phosphorylcholine. VIII. Evidence that antibodies bearing T15 idiotypic determinants in Ighj mice comprise a family of antibodies. J Immunol (1980) 0.96
Clonal nature of the immune response to phosphorylcholine. III. Species-specific binding characteristics of rodent anti-phosphorylcholine antibodies. J Immunol (1974) 0.93
Antibody affinity in mice with the CBA/N defect. J Immunol (1980) 0.89
Proceedings of Local Branches of the Society of American Bacteriologists. Eastern Pennsylvaniaand New York City Branches. J Bacteriol (1937) 0.89
AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood (1997) 7.84
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med (1995) 6.23
TAMBIS: transparent access to multiple bioinformatics information sources. Bioinformatics (2000) 6.02
BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A (1991) 5.50
Spatial patterns in the distribution of tropical tree species. Science (2000) 5.46
Analysis of actinomycete communities by specific amplification of genes encoding 16S rRNA and gel-electrophoretic separation in denaturing gradients. Appl Environ Microbiol (1997) 5.34
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal Chem (1999) 5.03
Subclass restriction of murine anti-carbohydrate antibodies. J Immunol (1978) 4.99
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis (1992) 3.52
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J Natl Cancer Inst (1994) 3.32
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Subclass restriction of murine antibodies. II. The IgG plaque-forming cell response to thymus-independent type 1 and type 2 antigens in normal mice and mice expressing an X-linked immunodeficiency. J Exp Med (1980) 3.13
Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis. J Bacteriol (1992) 3.05
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun (1991) 2.96
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Transformation of encapsulated Streptococcus pneumoniae. J Bacteriol (1986) 2.82
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Coma in the Wernicke-Korsakoff syndrome. Lancet (1978) 2.74
Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun (2000) 2.64
Prevalence of the factor VLeiden mutation among autopsy patients with pulmonary thromboembolic disease using an improved method for factor VLeiden detection. Am J Clin Pathol (1999) 2.55
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med (1997) 2.48
Vaccinating boys against HPV. Br Dent J (2013) 2.48
Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog (1997) 2.41
Monoclonal vs. heterogeneous anti-H-8 antibodies in the analysis of the anti-phosphorylcholine response in BALB/c mice. Eur J Immunol (1981) 2.33
Anti-DNA autoantibodies in (NZB X NZW)F1 mice are clonally heterogeneous, but the majority share a common idiotype. J Immunol (1982) 2.25
Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog (1994) 2.20
Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun (1982) 2.19
The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16
Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae. Nature (1981) 2.16
Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med (1992) 2.15
Immunoglobulin gene rearrangement in immature B cells. Science (1980) 2.14
Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis (2000) 2.11
Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine (2000) 2.07
A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun (1995) 2.01
Competition among Streptococcus pneumoniae for intranasal colonization in a mouse model. Vaccine (2000) 2.00
Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis (1996) 1.97
Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology (1999) 1.94
Coeliac disease. The clinical presentation. Clin Gastroenterol (1974) 1.89
Physical inactivity, sedentary lifestyle and obesity in the European Union. Int J Obes Relat Metab Disord (1999) 1.88
Coffee berry borer Hypothenemus hampei (Coleoptera: Curculionidae): searching for sustainable control strategies. Bull Entomol Res (2006) 1.87
Prevalence of physical activity during leisure time in the European Union. Med Sci Sports Exerc (2001) 1.87
IgG anti-DNA autoantibodies within an individual autoimmune mouse are the products of clonal selection. J Immunol (1989) 1.81
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoid. Infect Immun (1985) 1.77
The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol (2001) 1.77
Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants. Proc Natl Acad Sci U S A (1981) 1.77
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
A classification of tasks in bioinformatics. Bioinformatics (2001) 1.73
Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia. J Immunol (1984) 1.72
The primary effect of the Ity locus is on the rate of growth of Salmonella typhimurium that are relatively protected from killing. J Immunol (1990) 1.71
The IS1167 insertion sequence is a phylogenetically informative marker among isolates of serotype 6B Streptococcus pneumoniae. J Mol Evol (1998) 1.68
Differences in virulence for mice among Streptococcus pneumoniae strains of capsular types 2, 3, 4, 5, and 6 are not attributable to differences in pneumolysin production. Infect Immun (1997) 1.67
A controlled trial of hypotensive agents in hypertension in pregnancy. Lancet (1968) 1.64
Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog (1986) 1.64
Journal reading habits of internists. J Gen Intern Med (2000) 1.63
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol (1995) 1.61
Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae. Infect Immun (1996) 1.60
Invertebrate responses to the management of genetically modified herbicide-tolerant and conventional spring crops. II. Within-field epigeal and aerial arthropods. Philos Trans R Soc Lond B Biol Sci (2003) 1.58
Invertebrate responses to the management of genetically modified herbicide-tolerant and conventional spring crops. I. Soil-surface-active invertebrates. Philos Trans R Soc Lond B Biol Sci (2003) 1.57
Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association. Cancer (1972) 1.57
Production of monoclonal murine antibodies to DNA by somatic cell hybrids. Arthritis Rheum (1980) 1.56
Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015. Euro Surveill (2015) 1.56
Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med (1994) 1.55
The hemolytic and complement-activating properties of pneumolysin do not contribute individually to virulence in a pneumococcal bacteremia model. Microb Pathog (1997) 1.55
Immunoglobulin subclass-specific immunodeficiency in mice with an X-linked B-lymphocyte defect. J Exp Med (1979) 1.54
Foot-and-mouth disease in man. Br Med J (1967) 1.54
Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae. Microb Pathog (1990) 1.53
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
Expression, purification and characterization of recombinant murine granulocyte-macrophage colony-stimulating factor and bovine interleukin-2 from yeast. Gene (1987) 1.50
Gastrointestinal presentation of Langerhans cell histiocytosis in a child with perianal skin tags: a case report. J Pediatr Gastroenterol Nutr (2004) 1.50
Studies on the inhibition of C56 initiated lysis (reactive lysis). I. Description of the phenomenon and methods of assay. Immunology (1974) 1.49
Preliminary evidence from Queensland that rural clinical schools have a positive impact on rural intern choices. Rural Remote Health (2004) 1.49
A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun (1991) 1.48
Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane. Microb Pathog (1992) 1.48
Monoclonal antibodies to Salmonella lipopolysaccharide: anti-O-polysaccharide antibodies protect C3H mice against challenge with virulent Salmonella typhimurium. J Immunol (1984) 1.48
Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol (1983) 1.45
A 'safe-site' for Salmonella typhimurium is within splenic polymorphonuclear cells. Microb Pathog (1992) 1.44
Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol (1994) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Blood clearance of Streptococcus pneumoniae by C-reactive protein. J Immunol (1987) 1.42
Characterization of binding of human lactoferrin to pneumococcal surface protein A. Infect Immun (2001) 1.40
[The perception of body image as a qualitative approach to nutritional status]. Salud Publica Mex (2000) 1.40
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog (1992) 1.39
Infection control and contaminated waste disposal practices in Southern Sydney Area Health Service Dental Clinics. Aust Dent J (1997) 1.39
Escherichia coli O157 incident associated with a farm open to members of the public. Commun Dis Public Health (1999) 1.39
Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet (1989) 1.38
A 'safe-site' for Salmonella typhimurium is within splenic cells during the early phase of infection in mice. Microb Pathog (1991) 1.35
A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniae. Infect Immun (1998) 1.33
Identification of epilepsy genes in human and mouse. Annu Rev Genet (2001) 1.32
Family-based programmes for preventing smoking by children and adolescents. Cochrane Database Syst Rev (2007) 1.32
Evidence for separate genetic defects in C3H/HeJ and C3HeB/FeJ mice, that affect susceptibility to gram-negative infections. J Immunol (1985) 1.32